Key Points
- CEO Eran Ophir sold 5,000 shares of Compugen on April 14 at an average price of $2.90 under a Rule 10b5-1 plan (proceeds $14,500), trimming his holding to 11,375 shares; he also sold 5,625 shares on April 1 at $2.21.
- Compugen materially beat quarterly expectations, reporting $0.60 EPS vs. a $0.05 consensus and $67.33M in revenue vs. $14.30M expected, though analysts still model -$0.03 EPS for the current fiscal year.
- The stock trades near $2.89 with a consensus rating of "Moderate Buy" and an average price target of $5.00, while institutional ownership is ~12.22% with recent stake increases from firms like Renaissance and Jane Street.
Compugen Ltd. (NASDAQ:CGEN - Get Free Report) CEO Eran Ophir sold 5,000 shares of the company's stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $2.90, for a total transaction of $14,500.00. Following the transaction, the chief executive officer owned 11,375 shares in the company, valued at approximately $32,987.50. The trade was a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Eran Ophir also recently made the following trade(s):
- On Wednesday, April 1st, Eran Ophir sold 5,625 shares of Compugen stock. The stock was sold at an average price of $2.21, for a total transaction of $12,431.25.
Compugen Trading Up 0.3%
CGEN opened at $2.89 on Thursday. The company's fifty day moving average price is $2.07 and its two-hundred day moving average price is $1.84. Compugen Ltd. has a 1-year low of $1.23 and a 1-year high of $2.94. The company has a market cap of $273.25 million, a price-to-earnings ratio of 7.81 and a beta of 2.77.
Compugen (NASDAQ:CGEN - Get Free Report) last released its quarterly earnings data on Monday, March 2nd. The biotechnology company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.55. Compugen had a net margin of 48.57% and a return on equity of 55.68%. The firm had revenue of $67.33 million for the quarter, compared to the consensus estimate of $14.30 million. As a group, equities analysts forecast that Compugen Ltd. will post -0.03 earnings per share for the current fiscal year.
Institutional Trading of Compugen
Institutional investors have recently made changes to their positions in the company. State Street Corp grew its stake in shares of Compugen by 3.9% in the 4th quarter. State Street Corp now owns 393,802 shares of the biotechnology company's stock worth $603,000 after acquiring an additional 14,701 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Compugen by 3.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,456,900 shares of the biotechnology company's stock worth $2,229,000 after acquiring an additional 51,565 shares in the last quarter. Jane Street Group LLC grew its stake in shares of Compugen by 1,077.0% in the 2nd quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company's stock worth $700,000 after acquiring an additional 359,785 shares in the last quarter. Two Sigma Investments LP grew its stake in shares of Compugen by 10.6% in the 3rd quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company's stock worth $291,000 after acquiring an additional 18,929 shares in the last quarter. Finally, Marshall Wace LLP grew its stake in shares of Compugen by 135.7% in the 4th quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company's stock worth $163,000 after acquiring an additional 61,202 shares in the last quarter. Institutional investors own 12.22% of the company's stock.
Wall Street Analysts Forecast Growth
CGEN has been the topic of several research reports. HC Wainwright initiated coverage on shares of Compugen in a report on Wednesday, January 7th. They set a "buy" rating and a $4.00 price objective on the stock. Truist Financial upgraded shares of Compugen to a "strong-buy" rating in a report on Wednesday, March 25th. Lake Street Capital initiated coverage on shares of Compugen in a report on Tuesday, April 7th. They set a "buy" rating and a $6.00 price objective on the stock. Wall Street Zen upgraded shares of Compugen from a "hold" rating to a "buy" rating in a report on Saturday, March 7th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Compugen in a report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $5.00.
Read Our Latest Stock Report on CGEN
Compugen Company Profile
(
Get Free Report)
Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.
Compugen's predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
